Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denosumab biosimilar - Teva Pharmaceutical

Next Previous
X
Search
Drug Profile

Denosumab biosimilar - Teva Pharmaceutical

Alternative Names: TVB-009; TVB-009P

Latest Information Update: 15 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Bone disorders; Bone metastases; Giant cell tumour of bone; Male osteoporosis; Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 15 Oct 2024 Preregistration for Postmenopausal osteoporosis (In the elderly, In adults) in USA (SC)
  • 08 Oct 2024 Preregistration for Bone disorders (First-line therapy) in European Union (SC)
  • 08 Oct 2024 Preregistration for Bone disorders (First-line therapy) in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top